Dynamics of gene expression profiling and identification of high-risk patients for severe COVID-19

Rombauts, Alexander; Bódalo-Torruella, Marta; Abelenda-Alonso, Gabriela; Perera Bel, Júlia; Ferrer Salvador, Anna; Acedo-Terrades, Ariadna; Gabarrós-Subirà, Maria; Oriol, Isabel; Gudiol, Carlota; Nonell Mazelon, Lara, 1972-; Carratalà, Jordi

doi:http://dx.doi.org/10.3390/biomedicines11051348

Dynamics of gene expression profiling and identification of high-risk patients for severe COVID-19

License

Citation

Rombauts A, Bódalo Torruella M, Abelenda-Alonso G, Perera-Bel J, Ferrer-Salvador A, Acedo-Terrades A, Gabarrós-Subirà M, Oriol I, Gudiol C, Nonell L, Carratalà J. Dynamics of gene expression profiling and identification of high-risk patients for severe COVID-19. Biomedicines. 2023 May 3;11(5):1348. DOI: 10.3390/biomedicines11051348

Abstract

The clinical manifestations of SARS-CoV-2 infection vary widely, from asymptomatic infection to the development of acute respiratory distress syndrome (ARDS) and death. The host response elicited by SARS-CoV-2 plays a key role in determining the clinical outcome. We hypothesized that determining the dynamic whole blood transcriptomic profile of hospitalized adult COVID-19 patients and characterizing the subgroup that develops severe disease and ARDS would broaden our understanding of the heterogeneity in clinical outcomes. We recruited 60 hospitalized patients with RT-PCR-confirmed SARS-CoV-2 infection, among whom 19 developed ARDS. Peripheral blood was collected using PAXGene RNA tubes within 24 h of admission and on day 7. There were 2572 differently expressed genes in patients with ARDS at baseline and 1149 at day 7. We found a dysregulated inflammatory response in COVID-19 ARDS patients, with an increased expression of genes related to pro-inflammatory molecules and neutrophil and macrophage activation at admission, in addition to an immune regulation loss. This led, in turn, to a higher expression of genes related to reactive oxygen species, protein polyubiquitination, and metalloproteinases in the latter stages. Some of the most significant differences in gene expression found between patients with and without ARDS corresponded to long non-coding RNA involved in epigenetic control.